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OBJECTIVES This study sought to determine whether there are race and gender differences in the
distribution of C-reactive protein (CRP) levels.
BACKGROUND Few data are available comparing CRP distributions in different race and gender groups.
Recent clinical practice recommendations for CRP testing for cardiovascular risk assessment
suggest a uniform threshold to define high relative risk (3 mg/l).
METHODS We measured CRP in 2,749 white and black subjects ages 30 to 65 participating in the Dallas
Heart Study, a multiethnic, population-based, probability sample, and compared levels of
CRP between different race and gender groups.
RESULTS Black subjects had higher CRP levels than white subjects (median, 3.0 vs. 2.3 mg/l; p 
0.001) and women had higher CRP levels than men (median, 3.3 vs. 1.8 mg/l; p  0.001).
The sample-weight adjusted proportion of subjects with CRP levels 3 mg/l was 31%, 40%,
51%, and 58% in white men, black men, white women, and black women, respectively (p 
0.05 for each group vs. white men). After adjustment for traditional cardiovascular risk
factors, estrogen and statin use, and body mass index, a CRP level 3 mg/l remained more
common in white women (odds ratio [OR] 1.6; 95% confidence interval [CI] 1.1 to 2.5) and
black women (OR 1.7; 95% CI 1.2 to 2.6) but not in black men (OR, 1.3; 95% CI, 0.8 to
1.9) when compared with white men.
CONCLUSIONS Significant race and gender differences exist in the population distribution of CRP. Further
research is needed to determine whether race and gender differences in CRP levels contribute
to differences in cardiovascular outcomes, and whether thresholds for cardiovascular risk
assessment should be adjusted for different race and gender groups. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.0512005;46:464–9) © 2005 by the American College of Cardiology Foundation
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d-reactive protein (CRP) is the most extensively studied
nflammatory risk marker, and a series of prospective epi-
emiologic studies have shown that higher levels of CRP are
ssociated with incident cardiac and vascular events in
ealthy men and women (1–9). Recent clinical practice
ecommendations from the Centers for Disease Control and
revention (CDC) and the American Heart Association
AHA) support the use of CRP testing in selected patients
o help assess cardiovascular (CV) risk (10), and trials are
nderway to explore therapeutic strategies based on CRP
evels (11).
Current recommendations for CRP testing suggest uni-
orm CRP thresholds to characterize the relative risk of CV
vents based on approximate tertile values in several popu-
ations (10). Because these populations predominantly con-
ist of white subjects, it is unclear whether the recom-
ended thresholds appropriately reflect CRP distributions
or black men and women. Only limited comparisons of
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005, accepted April 19, 2005.RP levels between black subjects and white subjects have
een performed (12–14), and few data are available regard-
ng the prognostic utility of CRP values in black subjects.
Identical CRP thresholds are also suggested for men and
omen (10). To date, comparisons of CRP levels between
en and women have largely been performed across heter-
geneous clinical trial cohorts that may not accurately reflect
he general population (15). Only limited data are available
irectly comparing the distribution of CRP levels between
en and women within the same study population
13,16,17).
Given the paucity of available data regarding CRP
istributions in different race and gender groups and the
ncreasing interest in CRP for risk prediction, we sought to
etermine whether race and gender differences exist in the
istribution of CRP levels using data from the Dallas Heart
tudy, a large, multiethnic, population-based sample.
ETHODS
tudy population. The Dallas Heart Study is a multieth-
ic, population-based, probability sample of 6,101 subjects
n Dallas County, and was designed to study CV disease.
etails of the study design and characteristics of the
nrolled cohort (18) and variable definitions (19) have been
escribed previously. Briefly, a random probability sample of
allas County residents ages 18 to 65 years old was
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August 2, 2005:464–9 Race, Gender, and CRPbtained from a pool of 841,943 eligible subjects using the
.S. Postal Service Delivery Sequence File, with deliberate
versampling of black subjects. All participants provided
nformed consent to participate in the study, and the
rotocol was approved by the Institutional Review Board of
he University of Texas Southwestern Medical Center. The
nitial visit for all 6,101 participants included a detailed
n-home interview for demographic and health-related data,
s well as measurements of weight, heart rate, and five
equential blood pressure measures. All subjects between the
ges of 30 and 65 years who completed the initial visit were
nvited to participate in a second visit to collect fasting
enous blood and urine samples. No significant differences
ere noted in demographics, medical history, blood pres-
ure, or body mass index (BMI) among subjects participat-
ng in the home interview and the phlebotomy visit (18).
ampling weights, reflecting the different probabilities of
election for participants and sample attrition between visits,
ere constructed to generate unbiased estimates of popula-
ion frequencies (18). The present analyses were restricted
o white and black subjects who completed the second visit
2,749 of 3,398 total subjects completing the second visit)
ecause sample sizes in other race and ethnic groups were
imited. Race/ethnicity was determined by subject
elf-report.
igh-sensitivity CRP assay. Blood samples were obtained
fter an overnight fast in ethylenediamine tetra-acetic acid
ubes and were stored for 4 h at 4°C before processing.
lasma aliquots were frozen at 80°C until assays were
erformed. High-sensitivity CRP measurements were per-
ormed on thawed samples using the Roche/Hitachi 912
ystem, Tina-quant assay (Roche Diagnostics, Indianapolis,
Table 1. Baseline Clinical Characteristics of D
White Men
(n  475)
Age (yrs) 45.1 (12.6)
HTN (%) 26.3
Smoking (%) 24.7
Diabetes (%) 6.2
Elevated cholesterol (%) 13.9
Low HDL (%) 43.6
Elevated triglycerides (%) 18.7
Family history of CAD (%) 30.1
BMI (kg/m2) 28.9 (7.2)
Creatinine (mg/dl) 0.98 (0.2)
Estrogen use (%) —
Statin use (%) 7.0
Abbreviations and Acronyms
AHA American Heart Association
BMI  body mass index
CDC Centers for Disease Control and Prevention
CRP  C-reactive protein
CV  cardiovascularBMI  body mass index; CAD  coronary artery disease; HDL ndiana), a latex-enhanced immunoturbidimetric method
20). The minimal detectable range of this assay is 0.1 mg/l,
nd the upper limit is 20 mg/l. Clinical validation of this
ssay has been described previously (21).
tatistical analysis. Categorical data are reported as pro-
ortions and continuous data as mean values with standard
eviations. Baseline demographic variables and CV risk
actors were adjusted for sample weights and compared
cross categories of CRP using the chi-square trend test for
ategorical variables and the test for trend across ordered
roups for continuous variables. The CRP values were
djusted for sample weights and compared between race and
ender groups using the analysis of variance test for four
roup comparisons and the t test for two group compari-
ons. The results of these analyses were unchanged when
og-transformed CRP values were used, and only the
on-transformed data are shown. Log-transformed CRP
alues were also used in multivariable linear regression
odels in which CRP was the dependent variable. Subjects
ere categorized according to the CDC/AHA cut points
or CRP into three relative risk groups: low-risk (1 mg/l),
ntermediate-risk (1 to 3 mg/l) and high-risk (3 mg/l)
roups. Comparisons of the frequency of high-risk CRP
evels for each race and gender group were performed using
he chi-square test, with white men as the referent group.
djusted odds ratios for CRP values 3 mg/l for each
ace/gender group (compared with white men) were deter-
ined using multivariable logistic regression models that
ncluded traditional CV risk factors as covariates, and using
ampling weights. Analyses were performed using Stata
ersion 8.2 (Stata Corp. LP, College Station, Texas) and
UDAAN version 9 (Research Triangle Institute, Research
riangle Park, North Carolina).
ESULTS
he baseline characteristics of the four different race and
ender groups are shown in Table 1. Compared with white
ubjects, black men and women had a significantly higher
revalence of diabetes and hypertension. Black women had a
nt Race and Gender Groups
te Women
 516)
Black Men
(n  740)
Black Women
(n  1,018)
.8 (13.2) 43.7 (13.0) 43.5 (16.2)
25.4 37.7 42.4
26.2 32.0 26.3
6.1 12.4 10.9
14.2 14.8 12.1
41.2 26.0 46.1
12.2 12.3 6.5
42.3 31.3 32.5
.0 (8.2) 29.6 (8.7) 33.0 (17.8)
77 (0.2) 1.10 (0.3) 0.85 (1.0)
37.4 — 10.9
7.2 5.6 5.9iffere
Whi
(n
46
29
0.high-density lipoprotein cholesterol; HTN  hypertension.
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Race, Gender, and CRP August 2, 2005:464–9igher BMI and used estrogen less often than white women.
lack men had the highest prevalence of tobacco use.
Subjects were unequally distributed across CRP risk
ategories (CRP 1 mg/l, n  546 [20%]; CRP 1 to 3
g/l, n  848 [31%]; CRP 3 mg/l, n  1,355 [49%])
Table 2). As summarized in Tables 2 and 3, increasing
RP levels were associated with a number of CV risk
actors in unadjusted analyses. Importantly, female gender
nd black race were both associated with higher CRP levels.
he correlation between CRP and BMI was stronger than
he correlation between CRP and any other continuous
ariable, including age and all measured lipid risk factors,
nd was greater in women compared with men (Table 3).
Black subjects had higher CRP levels than white subjects
median, 3.0 vs. 2.3 mg/l; p  0.001) and women had
igher CRP levels than men (median, 3.3 vs. 1.8 mg/l; p 
.001) (Fig. 1). In multivariate analyses adjusting for tradi-
ional CV risk factors, BMI, and estrogen and statin use,
ace and gender were independently associated with log
RP levels (p  0.05 for each). Black men, white women,
nd black women all had higher CRP levels compared with
hite men, with the highest levels observed among black
omen (Fig. 2). Excluding users of 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors (statins)
nd oral estrogen had little effect on the CRP differences
etween black and white subjects (median, 2.6 vs. 2.1 mg/l;
Table 2. Association Between C-Reactive Prot
Clinical Variables
CRP <1 mg/l
(n  546)
Age (yrs) 42.8 (14.7)
Female (%) 40.7
Black (%) 25.8
HTN (%) 14.1
Smoking (%) 22.6
Diabetes (%) 2.0
Elevated cholesterol (%) 11.0
Low HDL (%) 26.2
Elevated triglycerides (%) 9.4
Family history of CAD (%) 30.0
BMI (kg/m2) 25.8 (5.8)
Creatinine (mg/dl) 0.93 (0.5)
Estrogen use (%) 4.3
Statin use (%) 6.8
*p value for trend.
CRP  C-reactive protein; other abbreviations as in Tab
able 3. Correlation Between C-Reactive Protein Levels and Co
White Men Black M
Correlation
Coefficient p Value
Correlation
Coefficient
MI 0.32 0.001 0.29
ge 0.06 0.16 0.17
otal cholesterol 0.13 0.005 0.08
DL 0.13 0.004 0.11
DL 0.24 0.001 0.16
riglycerides 0.17 0.001 0.10DL  low-density lipoprotein cholesterol; other abbreviations as in Table 1. 0.001) or the differences between women and men
median, 2.7 vs. 1.8 mg/l; p 0.001). In a similar sensitivity
nalysis, exclusion of these subjects only slightly attenuated
he differences in median CRP levels among the four
emographic groups (white men, 1.8 mg/l; black men, 2.0
g/l; white women, 2.6 mg/l; black women, 3.2 mg/l; p 
.001).
The proportion of subjects with high-risk CRP levels
ccording to the CDC/AHA practice recommendation was
stimated for each race and gender group (Table 4). Black
en, white women, and black women were significantly
ore likely to have CRP values in the high-risk range
ompared with white men, with almost two-thirds of black
omen having CRP levels 3 mg/l. These differences
ersisted after excluding statin and estrogen users and after
ample-weight adjustment (Table 4). Adjustment for tradi-
ional CV risk factors, BMI, statin and estrogen use, and
ampling weights attenuated the differences between race
nd gender groups, yet an elevated CRP level remained
ore common in white women and black women than in
hite men (odds ratio [OR] 1.6, 95% confidence interval
CI] 1.1 to 2.5, p  0.05; and OR 1.7, 95% CI 1.2 to 2.6,
 0.05, respectively) (Fig. 3). In contrast, the differences
etween black men and white men were no longer statisti-
ally significant after multivariate adjustment (OR 1.3; 95%
I 0.8 to 1.9).
isk Categories and Demographic and
P 1 to 3 mg/l
(n  848)
CRP >3 mg/l
(n  1,355) P Value*
45.1 (16.3) 46.8 (16.9) 0.001
41.9 61.9 0.001
24.3 32.3 0.007
30.3 38.1 0.001
25.3 29.2 0.1
5.6 12.4 0.001
11.1 17.5 0.007
40.4 49.4 0.001
11.6 17.8 0.002
33.4 38.5 0.06
28.4 (6.7) 32.7 (12.9) 0.001
0.92 (0.3) 0.87 (0.4) 0.02
11.9 22.1 0.001
5.3 7.8 0.3
ous Variables
White Women Black Women
alue
Correlation
Coefficient p Value
Correlation
Coefficient p Value
.001 0.58 0.001 0.51 0.001
.001 0.15 0.001 0.21 0.001
.03 0.16 0.001 0.06 0.05
.001 0.12 0.006 0.10 0.002
.001 0.18 0.001 0.25 0.001
.009 0.38 0.001 0.24 0.001ein R
CRntinu
en
p V
0
0
0
0
0
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August 2, 2005:464–9 Race, Gender, and CRPAn increasing BMI was associated with higher CRP
evels in each race and gender group (p  0.001 for each),
ut the increase in CRP levels with obesity was greater for
omen than for men (p value for interaction of obesity and
ender on log CRP levels 0.001) (Fig. 4).
ISCUSSION
n a large, multiethnic, population-based sample, we ob-
erved that black subjects have significantly higher CRP
evels than white subjects, and women have significantly
igher CRP levels than men. These findings persisted after
xclusion of subjects taking statins and oral estrogen, and
fter adjustment for traditional CV risk factors and BMI.
he associations were robust whether CRP was considered
s a continuous or as a categorical variable (CRP 3 mg/l).
iven the increasing use of CRP as a component of CV risk
rediction, and the potential future use of CRP in clinical
ecision-making, our findings have important public health
mplications.
omparison with other studies. The potential for impor-
ant racial and ethnic differences in CRP levels has been
hown in studies of other ethnic groups (22–24). However,
tudies comparing CRP levels between black and white
opulations are limited (13,14,17,25), and the major studies
xamining the relationship between CRP levels and CV
vents have included few if any black subjects (1–9). The
ational Health and Nutrition Examination Survey 1999 to
igure 1. Comparison of C-reactive protein (CRP) levels between white
nd black subjects, and between men and women. Data are shown as
edians (25th and 75th percentiles); p  0.001 for each comparison.
Table 4. Proportion of Subjects with C-Reacti
Whit
CRP 3 mg/l, (%) 2
p value* —
CRP 3 mg/l, sample-weight adjusted, (%) 3
p value* —
CRP 3 mg/l, excluding statin and
estrogen use (%)
2
p value* —
CRP 3 mg/l, excluding statin and estrogen
use, sample-weight adjusted (%)
3
p value* —*p value for comparison with white men.
CRP  C-reactive protein.000 compared CRP levels in black and white men age20
ears, an age range younger than in the current study (14).
lthough the investigators concluded that CRP levels were
imilar between black and white men based on median
alues, the upper tertiles for black men ages 45 to 64 years
nd 65 years were 5.4 and 7.0 mg/l, respectively, com-
ared with 3.2 and 3.7 mg/l in white men. A similar analysis
n women was performed using the same database and
howed that the median CRP level in black women was 3.5
g/l compared with 2.5 mg/l in white women (13). These
ifferences persisted after excluding users of hormone re-
lacement therapy, but data on statin use were not available.
ecently, one study explored ethnic differences in CRP
evels in women and found that black women had higher
RP levels than white women (25). However, this study
onsisted of a clinical trial cohort of postmenopausal women
ith much higher rates of estrogen use, lower BMI mea-
ures, and lower CRP values than our population-based
ample. The present population-based study showed that in
allas County, which likely represents a typical multiethnic
.S. urban population, the median CRP level was 30%
igher in black subjects than in white subjects.
Previously, CRP levels were thought to be similar be-
ween women and men (15,26). However, these conclusions
ere based on comparisons of CRP levels across different
tudies with heterogeneous study populations, rather
han on direct comparisons between men and women
igure 2. Comparison of C-reactive protein (CRP) levels between differ-
nt race and gender groups. Data are shown as medians (25th and 75th
ercentiles); p  0.001.
otein Levels 3 mg/l
n Black Men White Women Black Women
42.3 50.4 63.4
0.001 0.001 0.001
39.7 51.2 57.5
0.03 0.001 0.001
41.4 42.7 59.7
0.001 0.001 0.001
37.9 43.7 53.8
0.1 0.009 0.001ve Pr
e Me
9.1
0.9
9.4
1.6
w
l
g
C
c
H
t
l
p
C
w
h
h
h
t
i
fi
i
C
r
t
s
A
p
p
h
p
p
f
p
a
A
c
r
p
s
l
e
i
o
e
o
i
c
b
t
r
l
s
o
t
r
w
w
C
I
n
C
C
S
m
t
r
g
A
T
m
r
R
o
H
F
p
s
f
t
c
F
b
f
e
l
468 Khera et al. JACC Vol. 46, No. 3, 2005
Race, Gender, and CRP August 2, 2005:464–9ithin the same sample. Moreover, these studies were
argely performed in volunteers, who may differ from the
eneral population in important ways. No differences in
RP levels between men and women were found in a
ompilation of European population-based studies (27).
owever, direct comparisons in U.S. research popula-
ions suggest that there may be gender differences in CRP
evels (13,16). In our study of a large, contemporary, U.S.
opulation-based sample, we observed that the median
RP level was almost twice as high in women compared
ith men.
Our contemporary, urban, and unselected cohort has a
igher prevalence of overweight and obese subjects than
as been reported in previous studies of CRP from more
ighly selected research populations (4,5,25). We found
hat increases in BMI were associated with much greater
ncreases in CRP in women than in men (Fig. 4), a
nding that may in part explain gender-based differences
n CRP levels.
linical and public health implications. The finding of
ace and gender-based differences in CRP levels has impor-
ant implications for the clinical use of CRP. Our findings
uggest that the CRP risk categories outlined in the CDC/
HA statement, which were derived from selected research
opulations, may not be reflective of a contemporary,
redominantly urban, multiethnic population with very
igh rates of obesity.
Several different interpretations of our findings are
ossible. Higher CRP levels in black subjects, and in
articular in black women, may portend an increased risk
or future CV events. Black subjects have a greater
revalence of CV risk factors than white subjects (28,29),
nd higher CRP levels may reflect this risk factor burden.
lso, racial differences in inflammation may directly
ontribute to the higher coronary heart disease mortality
ates in black subjects (30). On the other hand, it is also
ossible that reliance on CRP for risk assessment in black
igure 3. Adjusted odds ratios and 95% confidence intervals for C-reactive
rotein (CRP) levels 3 mg/l. White men are the referent group. Filled
quares  adjusted for sample weights only; filled diamonds  adjusted
or age, diabetes, hypercholesterolemia, high-density lipoprotein choles-
erol, hypertension, smoking, body mass index, estrogen use, statin use,
reatinine, and sample weights.ubjects may overestimate the risk for cardiac and vascu- Ear events, and could lead to overuse of resources. For
xample, if a CRP value 3 were used as a criterion for
nitiating a therapeutic intervention, approximately 50%
f black subjects between 30 and 65 years of age would be
ligible for this intervention in Dallas County. Because
ur study uses a cross-sectional design, the prognostic
mplications of the racial differences in CRP distributions
annot be determined: long-term outcome studies in
lack subjects are needed to determine the implications of
hese findings and to determine whether the CDC/AHA
isk thresholds are appropriate.
The clinical implications of gender differences in CRP
evels also require consideration. Several studies have
hown a strong association between CRP levels and CV
utcomes in women (4,6). It is not clear, however, that
he threshold for defining high-risk CRP levels for
esearch cohorts can be generalized to the population, in
hich obesity is highly prevalent and more than 50% of
omen have CRP values 3.
ONCLUSIONS
n this multiethnic population-based study, we found sig-
ificant race and gender differences in the distribution of
RP levels, with women and black subjects having higher
RP levels than men and white subjects, respectively.
tudies with long-term follow-up will be needed to deter-
ine whether these differences in CRP distribution con-
ribute to differences in clinical outcomes and whether CRP
isk thresholds should be adjusted for different race and
ender groups.
cknowledgments
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eview of the manuscript.
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igure 4. Relationship between C-reactive protein (CRP) levels and
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